

NEWSLETTER

CHEMICAL & PHARMACEUTICAL

24 – 30 November 2025



BeOne Medicines expands R&D innovation center in Beijing

BeOne Medicines has expanded its R&D innovation center in Beijing's Changping district. The new facility, located in Zhongguancun Life Science Park, significantly increases capacity to over 1,300 staff. It will enhance research in key areas like immuno-oncology and antibody-drug conjugates. This center is a vital part of the company's global R&D network, driving scientific breakthroughs for patients worldwide. **(China Daily)**

Medical firm thrives under Hainan's tax incentives

Susheng Biotech is thriving in Hainan, fueled by the province's favorable policies and tax incentives. The company has significantly reduced its management and production costs, saving nearly 20% on the latter due to zero tariffs. Benefits include a preferential 15% corporate income tax rate and access to streamlined approvals for advanced medical goods. **(China Daily)**

Jiangsu Hengrui gets conditional approval for new cancer drug

Jiangsu Hengrui Pharmaceuticals has received conditional approval from Chinese regulators for its new cancer drug, Zeprumetostat. The drug is China's first domestically developed EZH2 (Enhancer of Zeste Homolog 2) inhibitor, intended to treat relapsed or refractory peripheral T-cell lymphoma. This oral therapy offers a new treatment option for patients with this rare and aggressive blood cancer. **(China Daily)**

Turkey Issues Final Anti-Dumping Ruling on Polystyrene from China

The Turkish Ministry of Trade issued Announcement No. 2025/37, issuing a final affirmative anti-dumping ruling on polystyrene originating from mainland China, Taiwan, India, South Korea, Russia, and Thailand. The ruling imposes anti-dumping duties on the products for a period of five years based on the CIF price (see attached table). The duty rate for mainland China is 7.37%. **(China Trade Remedy Information Network)**

India Issues Final Ruling on Overseas-Produced Toluene Diisocyanate

The Indian Ministry of Commerce and Industry issued a notice making an affirmative final ruling in the first sunset review of the antidumping duty on toluene diisocyanate with an isomer ratio of 80:20 originating in or imported from the European Union and Saudi Arabia. The anti-dumping investigation into the aforementioned products originating in or imported from the European Union, Saudi Arabia and Taiwan was initiated in 2020. **(Website of the Directorate General of Trade Remedies, Ministry of Commerce and Industry, India)**